



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT).

(51) International Patent Classification ⁵ : G01N 33/94	A1	(11) International Publication Number: WO 93/18408 (43) International Publication Date: 16 September 1993 (16.09.93)
(21) International Application Number: PCT/IE93/00007 (22) International Filing Date: 1 March 1993 (01.03.93) (30) Priority data: 920668 2 March 1992 (02.03.92) IE (71) Applicant (for all designated States except US): ENFER TECHNOLOGY LIMITED [IE/IE]; Block A, Earlsfort Centre, Earlsfort Terrace, Dublin 2 (IE). (72) Inventor; and (75) Inventor/Applicant (for US only) : O'CONNOR, Michael [IE/IE]; 13 Chestnut Grove, Mount Merrion, Co. Dublin (IE). (74) Agents: GATES, Marie, Christina, Esther et al.; Tomkins & Co., 5 Dartmouth Road, Dublin 6 (IE).		(81) Designated States: AT, AU, BB, BG, BR, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: VETERINARY DRUG RESIDUE SURVEILLANCE IN FRESH MEAT (57) Abstract The invention relates to a rapid assay for the determination of drug residues in fresh meat or livestock. The assay allows the determination of results in approximately 90 minutes thus allowing certification of drug-free carcasses before they enter the food chain. The assay is an immunometric assay using chromogenic or chemiluminescent labels.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LI	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TG	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

- 1 -

5

10 Veterinary Drug Residue Surveillance in Fresh MeatTechnical Field

15 The present invention relates to a method for the rapid detection of veterinary drug residues in fresh meat or livestock and to a test kit for use in such a method.

Background of the Invention20 Field of the Invention

The illegal use of certain veterinary drugs has resulted in the development of a flourishing illicit market in these drugs which in turn presents a potential hazard for the consumer of produce from
25 treated animals.

Steers are traditionally used in the beef industry rather than bulls. Steers are less efficient, they grow 10% slower and have more fat and poorer conformation than bulls. Thus, beef producers used
30 anabolic agents to increase growth before they were banned. However, since the EC ban in 1987, there have been varying allegations of illegal use of prohibited production enhancers in beef cattle. The possibility that a significant portion of beef might have residues of illegal growth enhancers could threaten consumption of beef.

35

Mandatory testing by national authorities of fresh meat, in compliance with EC Directives, covers a range of veterinary medicines and banned substances.

- 2 -

The extent of monitoring in compliance with EC Directives and 'on suspicion' is limited by the resources available to the authorities and thus will inevitably result in only a limited number of samples being monitored. In addition to this, the analytical methods used
5 are laborious and costly. A further disadvantage of currently available commercial immunological assays is that they require at least one day for an end-point determination to be made. Thus the carcass being tested would have left the abattoir before the assay result is available.

10

The analytical test protocol of the present invention represents a new approach to surveillance of fresh meat for drug residues. The approach has been to apply rapid clinical diagnostic techniques to veterinary drug residue analysis. This has the potential to permit
15 large numbers of samples to be processed rapidly and much more cheaply than is currently the case. This approach permits the monitoring of large numbers of animals as they pass through abattoirs and offers the possibility of "Carcass Quality Certification (CQC) " before the carcass is allowed to enter the food chain.

20

The invention provides a series of semi-automated tests for a range of veterinary drugs, such as 'Angel Dust' (the Beta-Agonists- Clenbuterol, Salbutamol, Terbutaline etc), and for illegal hormonal growth promoters (Zeranol, Trenbolone, Stilbenes etc).

25

Object of the Invention

The object of the invention is to provide a rapid method of detection of veterinary drug residues in fresh meat or livestock, with results
30 being preferably available in a matter of hours. It is also an object that the detection method be cheap, reliable and user friendly.

Summary of the Invention

35 According to the present invention there is provided a method for the rapid detection of drug residues in livestock comprising taking a body sample from the livestock, reacting the sample in an immunometric assay with a labelled antibody which is capable of

- 3 -

reacting with the drug to be tested and determining the amount of labelled antibody bound to the sample, the antibody being labelled with a chromogenic label or a chemiluminescent label.

- 5 Preferably the sample is bile fluid. The antibody may be an anti-clenbuterol antibody or an anti-zeranol antibody.

The bile sample may be "cleaned" prior to immunometric assay to produce a sample containing only the analyte to be tested.

- 10 Preferably, the bile sample is passed through an immuno affinity column having an immobilized antibody directed against the drug to be tested, the column is washed free of impurities and any drug bound to the column is eluted with a solvent. Clenbuterol may be eluted with 0.3% hydrochloric acid.

15

- Preferably, the immunometric assay is a competitive assay in which a solid support (suitably a microtitration plate) is pre-coated with a carrier protein-drug conjugate, the "cleaned" bile sample and a rabbit anti-drug antibody are added to the solid support, allowed to react and the support washed, a labelled donkey anti-rabbit IgG antibody is added, allowed to react and then washed, a signal reagent is then added and the signal read. The label may be horseradish peroxidase, and the carrier protein may be thyroglobulin.

- 25 The immunometric assay may suitably employ the Amerlite (Trade Mark) enhanced luminescence system available from Amersham International.

- The assay may be fully automated with the extraction of the samples on the immuno-affinity column and the enzyme linked immunosorbent assay being performed by primary and secondary robots respectively.
- 30

The invention also relates to a test-kit for the detection of drug residues in livestock which comprises a labelled anti-drug residue antibody.

35

Preferably the anti-drug residue antibody is an anti-clenbuterol antibody, or an anti-zeranol antibody.

- 4 -

The present invention has shown that the anti-clenbuterol antibody shows sufficient cross-reactivity to enable the system to identify other beta agonists such as salbutamol, terbutaline etc. This has the advantage that as it becomes apparent to those using the illegal substances that clenbuterol (the currently most used beta-agonist) can easily be identified and they switch to using other beta agonists these also can be identified.

Brief Description of the Drawings

10

Figure 1 is a calibration curve for clenbuterol,

Figure 2 is a clenbuterol standard curve,

Figure 3 is a standard calibration curve generated in the presence of an untreated bile extract, and

15 Figure 4 is a standard calibration curve for zeranol.

Detailed Description of the Invention

Sample Matrix

20 Bile has been selected as the sample matrix of choice, as it is well established that the residues of the majority of veterinary drugs occur at a high concentration in this fluid. It is also readily obtainable and can be easily handled following collection.

25 Assay Development

The objective of the invention has been to develop a rapid surveillance test protocol involving the development of:

- a) A rapid sample purification protocol,
- 30 b) A rapid end point detection system

a. Sample Purification

Due to the extremely sensitive nature of the detection system and its susceptibility to interference from impurities in the sample matrix, it is essential to prepare a clean extract containing only the analyte(s) (e.g. Beta-Agonists or hormonal growth promoters).

- 5 -

Utilising immunoaffinity columns through which the sample is allowed to percolate, immobilised antibodies react immunochemically with drugs present in the sample, absorbing them from the solution, the impurities passing through the column. The column is then washed
5 with a buffer solution to remove any impurities remaining on the column, following this the drugs are eluted from the column with a specific solvent solution, to yield a clean sample extract which can be used in the end-point analysis.

10 The whole process is designed to permit the high degree of automation which will be necessary to permit the processing of large numbers of samples.

b. End Point Detection

15 This is an immunoassay which utilises an enhanced chemiluminescent end point. The test is conducted in 96 well microtitration plates, each of which permits about 40 samples (in duplicate) together with calibration standards, blanks and quality controls (QC), to be
20 analyzed. The assay is formatted in the following manner using Clenbuterol as an example. A conjugate of Clenbuterol coupled to a carrier protein (Thyroglobulin) is absorbed on the surface of the wells of a microtitration plate. Into the wells are pipetted a known amount of rabbit anti- Clenbuterol antibody and Clenbuterol standard
25 or sample extract, or QC, or Control (blank) extract. These are allowed to react immunochemically. Following this the contents of the wells are discarded and the wells washed with buffer solution. Into each well is pipetted a fixed amount of enzyme-labelled (Horse Radish Peroxidase) donkey anti- rabbit (IgG) antibody, this is
30 allowed to react immunochemically. The microtitration plates are then emptied and washed with buffer solution, 'Enhanced Luminescent' reagent is then pipetted into each well and allowed to react for a fixed period of time before the chemiluminescence is determined. Using this approach and protocol the analytical system is able to
35 provide a result of the Beta-Agonist residue status within about 2 hours of receiving the sample for analysis. In practical terms, allowing time for sample collection, processing and reporting of the result, 'carcase certification' can potentially be provided within

- 6 -

about 4 hours of the animal being slaughtered.

The assay of the present invention thus provides a one and a half hour immunoassay of bile for beta agonists with a sensitivity of 0.3 parts per billion which is lower than current UK and expected EC maximum residue limits (MRL). This provides reliable, repeatable, fast assay results with a daily throughput of up to 1,000 samples per machine per day, and will allow the introduction of routine screening of all cattle slaughtered in meat factories for residues of beta agonists. Thus, carcasses can be certified the same day by the veterinarian as free of residues before the carcass enters the human food chain and without disrupting the normal carcass processing and chilling routine in the factory. The fact that results are available within four hours of sample collection and the high throughput of the system on a daily basis are unique properties allowing all cattle slaughtered on a daily basis to be tested.

The system is such that it can rapidly adapt to screen for residues of new illegal drugs once antibodies have been generated against the illegal substance in question, and a suitable assay protocol is developed (<6 months in the case of a beta agonist test).

Target Assay Matrix:

Bile has been selected as the sample matrix of choice for assay. The residues of the majority of veterinary drugs occur at a high concentration in this fluid. It reflects concentrations of residues in the liver very accurately but has the advantage that it does not need to go through an initial tissue extraction step before preparation for assay. It is also readily obtainable and can be rapidly handled following collection. In some cases the concentration of residues of veterinary drugs in some edible tissues exceeds that in bile; however they are not readily extractable and may need extensive chemical manipulation prior to the final analysis.

- 7 -

Method of Collection of Bile Sample from Carcase

The main points to be considered in routine collection of bile samples are:

- 5
- (i) Correlation of TB tag number of animal with carcass number and with sample collected.
 - (ii) Non-disruptive sample collection method from individual
10 carcasses:- bile can be collected from each animal during evisceration of the animal.
 - (iii) Security of sample transfer to assay laboratory.

15 Assay Specification

Immunoaffinity Columns

Antibody: Rabbit and Sheep anti-clenbuterol antibody.

20 Immunoaffinity column matrix: Activated porous silica.

Immunoaffinity column container: Baker filtration columns.

Each column is filled with about 0.25 mls of porous silica to which the anti-clenbuterol antibody has been chemically bonded. Each
25 column is capable of processing in excess of about 2ml of bile although only 1ml of bile is processed at present. The chemical recovery of each column is better than 75% ($77.8\% \pm 3.8\%$, $n=9$). The re-usability of the column is in excess of 20 times without any loss of performance.

30

Immunoassay

Assay standards: 0 to 500pg (5) Quality Control Samples: Control Bile
spiked at two concentrations either side of the target sensitivity of
35 (0.5ppb) which is the proposed MRL.

- 8 -

Assay Sensitivity; Standard curve (B_0) = approx. 0.2ppb Assay Limit of Detection (B_{ile}): (mean bile $B_0 + 3SD$) = 2ppb

Antibody Cross reactivity:

Clenbuterol 100%

5 Salbutamol 14%

Within (Intra) assay variation : at 10%

Between (Inter) assay variation : at 10-15%

10 Assay Protocols

Immunoaffinity Column

1. Pre condition the column with 3ml of 0.3% Hydrochloric acid.
15
2. Wash the column with 3ml of distilled water or phosphate buffered saline (PBS).
3. Apply the bile sample (1ml) to the column and allow to
20 percolate through the column under gravity. (It is also possible to process 2ml of bile and use the column to concentrate the analyte, this will increase the sensitivity of the assay). A vacuum can be applied to assist completion of this or any of the other steps.
- 25 4. Wash the column with distilled water (3ml) or reverse osmosis grade water.
5. Elute the clenbuterol with 0.75ml of 0.3% Hydrochloric acid.
30
6. Add 0.25ml of 10 x concentrate of PBS to the column eluate.
7. This extract is taken forward to the assay.
- 35 To reuse the immunoaffinity column for the purification of additional samples:

- 9 -

8. Wash the column with 1ml of 50% ethanol/distilled water.
9. Wash the column with 1ml of 0.3% hydrochloric acid.
- 5 10. Repeat procedure from step 1.

Enhanced Chemiluminescent Immunoassay

To the wells of a microtitration plate pre-coated with a
10 Thyroglobulin - Clenbuterol conjugate, the following procedures are carried out:

1. Add 0.1ml per well of extracted sample, blank QC or standard as appropriate.
- 15 2. Add 0.1ml per well of rabbit anti-clenbuterol antibody diluted 1:50000 with PBS/Tween.
3. Shake for 40 minutes at 37°C, or at ambient temperature.
- 20 4. Wash 3 or 4 times with PBS/Tween 20 (0.05%).
5. Add 0.2ml per well of Enzyme labelled Donkey anti-rabbit IgG antibody, diluted 1:5000 in PBS/Tween.
- 25 6. Shake for 30 minutes at 37°C, or at ambient temperature.
7. Wash 3 or 4 times with PBS/Tween 20 (0.05%).
- 30 8. Add 0.15ml per well of Amerlite Signal Reagent and shake briefly.
9. Allow to stand for 3-10 minutes at ambient temperature then read the signal.
- 35 10. Data reduction test results printed out.

- 10 -

Sample Collection

The sample of bile is taken from the gall bladder attached to the liver while still in the abdomen of the carcass. The sample is taken
5 using a pre-coded vacutainer (tamper-proof) which corresponds to the actual number of the carcass slaughtered on that day. The sample taken on a daily basis is related to the carcass number on a daily basis. The sample is taken at the evisceration area. The sample taken will be situated at the evisceration stand and will remove the
10 sample before removal of the pluck.

Example 1: The determination of the Beta-Agonist clenbuterol residues in bile samples.

15 The following describes the procedure for the analysis of fresh bile samples obtained at the abattoir. The batch size is 40 which is equivalent to twice maximum capacity of the vacuum manifold currently used to process samples, the extracts from these samples (40) can be placed into one microtitration plate and analysed.

20

METHOD

Preparation of Clenbuterol Antibody

As clenbuterol will not stimulate an immune response when injected
25 directly into an animal, it must first be converted into a form which will do so. This is facilitated by coupling Clenbuterol to a carrier protein (Bovine Serum Albumin - BSA,).

Clenbuterol (20mg) in a glass vial, is dissolved in dilute sulphuric acid and cooled in an ice bath. To this solution is added sodium
30 nitrite solution, dropwise over a period of several minutes with stirring. After a further period of stirring, a solution containing the carrier protein (32mg) is added, stirring is continued for a further 4 hours. The Clenbuterol - protein conjugate is then
35 dialysed exhaustively against sodium bicarbonate buffer solution. Following the dialysis stage, any remaining uncoupled Clenbuterol and other constituents of the reaction mixture with the exception of the uncoupled protein are removed. (The presence of uncoupled protein in

- 11 -

this solution is of no importance, as the primary objective is to generate an antibody to Clenbuterol. The antibodies generated to the carrier protein are unlikely to interfere with the assay - to date, there is no evidence to suggest that there is any interference of this nature, to the assay. If there were interference one can easily purify the anti-clenbuterol antibody and remove any antibodies to the carrier protein.)

The 'conjugate solution' is bottled and stored frozen until required for preparation of the immunising solution. It is assumed that all the clenbuterol has been conjugated to the carrier protein, but in practice this may not be the case.

Immunisation of Rabbits

The immunising solution is prepared immediately prior to use by thawing the frozen conjugate solution and allowing it to equilibrate to room temperature, mix gently. Pipette an appropriate volume equivalent to 1mg of Clenbuterol - protein conjugate, per rabbit, into a glass vial, adjust the volume to 0.5 ml times the number of rabbits to be immunised, with PBS solution. To this solution add an appropriate volume (0.5ml x the number of rabbits to be immunised) of Freund's Complete Adjuvant (Difco), emulsify the mixture and store at 4°C until required.

Each rabbit is immunised intra muscularly and subcutaneously with a total volume of 1ml of the emulsion. Booster injections using the same protocol are administered 3/4 weeks after the first immunisation. The animals are then left for a longer period (6/8 weeks) before the further boost injections. Tests bleeds are obtained both immediately prior to and about 10 days after each boost injection, the serum is separated and stored frozen at -20°C until required for evaluation.

Samples

Numbered vacutainers containing the samples are placed in sequence in suitably labelled racks. Fresh samples must be allowed to

- 12 -

equilibrate to room temperature before proceeding. (It is also possible to store samples frozen at -20°C , in which case the samples must be allowed to thaw and then thoroughly mixed prior to proceeding).

5

Extraction of the Clenbuterol from the Bile Samples

a) Immunoaffinity column preparation:

Immunoaffinity columns (20) are placed into the 20 place vacuum manifold. The columns are washed in sequence with 0.3% Hydrochloric Acid (1ml), the washes are discarded to waste. This is followed by washing each column with distilled water (1ml) followed by PBS (3ml), discarding the washes to waste. The columns are now ready to use for the extraction of bile samples.

15

b) Treatment of bile samples:

The equilibrated bile samples (5ml) are added to each column and allowed to percolate through the columns under gravity. When the samples have passed through the columns, the columns are then washed, under vacuum, with distilled water (2 x 1ml). Racks containing numbered sample tubes each containing 0.25ml of a 10 x concentrate of PBS are placed into the vacuum manifold. The columns are then eluted, under vacuum, into the respective samples tubes by pipetting 0.3% Hydrochloric Acid (0.75ml) on to each column. The rack containing the extracted samples is then removed from the vacuum manifold and transferred to the immunoassay stage. The columns can now be regenerated to permit re-use.

25

c) Immunoaffinity Column Regeneration.

The columns are regenerated for further use by washing with distilled water (1ml) followed by PBS (1ml). The columns are now prepared for recycling as described above.

30

Immunoassay of Extracted Bile Samples

35

The tubes containing the extracted bile samples (1ml), which have now been concentrated 5 - fold, are placed in sequence into the carousel of the Denley Wellprep dispenser. The analyte-coated microtitration

- 13 -

plate is washed with PBS/Tween 20 (0.3ml x 3) using a plate washer, the plates are inverted and tapped dry over paper towelling to remove excess liquid. The analyte coated microtitration plates used in the assay are coated with a Clenbuterol - protein conjugate (Clenbuterol - thyroglobulin), which is prepared in exactly the same manner as the immunogen, described above. The plate is then placed into the plate holder on the Wellprep. The dispensing programme is then initiated. Into pre - assigned wells of the microtitration plate is pipetted, in duplicate, an 0.1ml aliquot of either the standard or the extracted sample. This is followed by the addition of 0.1ml of the antibody diluted (1:50,000) in PBS. The plate is then removed from the Wellprep holder and transferred to a shaking incubator for 40 minutes at 37°C. Following this the plate is transferred to the plate washer and washed with PBS/Tween 20 (0.3ml x 3), the plate is then removed from the plate washer, inverted, and tapped dry over paper towelling to remove excess liquid. Using a Denley Wellfill, 0.2ml of Enzyme Labelled (Horse Radish Peroxidase - HRP) Donkey anti-rabbit IgG antibody diluted in PBS (1:5000) is dispensed into each well of the microtitration plate. The plate is then placed into the shaker incubator for a further period (30 minutes at 37°C). After the second incubation, the plate is placed in the plate washer and washed with PBS/Tween 20 (0.3ml x 3), removed from the plate washer, inverted and tapped dry over paper towelling to remove excess liquid. Using the Denley Wellfill to each well of the microtitration plate is added 0.15ml of Amerlite Signal Reagent (Amersham International). The plate is covered with a plastic cover or film and allowed to stand for 6 minutes prior to transferring to a chemiluminescence plate feeder.

30 Data Transformation (computation of results).

The output from the plate reader is entered manually into a commercial software graphics package (Harvard Graphics) to produce a standard calibration curve. The mean luminescence values are then read - off this calibration curve. Figure 1 shows a calibration curve for clenbuterol and Figure 2 shows a clenbuterol standard curve which may be used to determine the amount of clenbuterol in the bile sample. Figure 3 shows a standard calibration curve generated in

- 14 -

the presence of a control, untreated bile extract which demonstrates that the effect of a bile extract on the calibration curve is minimal, with little or no effect on the calibration curve containing only extract buffer.

5

RESULTS

The results shown in Table I were obtained on fresh bile samples collected at two abattoirs. The first batch of samples was from animals which were claimed to have originated from a guaranteed source and had not been treated with any illegal medication. These animals can be considered to be control (untreated) animals and thus provided a baseline from which to deduce if a bile sample from an animal of unknown origin is likely to have been illegally treated. The mean of these values + 3 Standard Deviations represents the Limit of Decision for the assay, values above this can be considered to be suspect and require further investigation. The confidence in this result is greater than 98%. The second batch of samples was from animals passing through an abattoir, the origin of these animals is unknown, they thus represent a 'field situation'.

25

30

35

- 15 -

TABLE I

Batch 1 - Untreated animals - Control		Batch 2 - Unknown origin - Abattoir	
Sample No.	Result - pg/ml	Sample No.	Result - pg/ml
46	30	36	54
47	25	37	55
48	30	38	47
49	33	39	75
50	30	40	60
51	30	41	57
52	10	42	45
53	0	43	33
54	30	44	30
66	0	45	36
67	0	46	60
68	0	47	27
69	5	48	48
70	7	49	75
71	0	50	79
72	15	51	75
73	150	52	70
74	0	53	65
75	18	54	50
		78	500 *
		101	360 *
		102	1,500 *
		103	39
		104	75
		105	450 *
		107	600 *
		109	400 *
		111	450 *
		112	1,200 *
		113	1,200 *
		114	170 *
		115	380 *
		116	60
		117	900 *
		123	21
		124	1,500 *
		125	8
		126	36

- 16 -

TABLE I Contd.

Batch 1 - Untreated animals - Control		Batch 2 - Unknown origin - Abattoir	
Sample No.	Result - pg/ml	Sample No.	Result - pg/ml
77	45	55	64
78	48	56	1,500 *
79	0	57	250 *
80	10	58	300 *
81	48	59	600 *
82	10	60	540 *
83	0	61	600 *
84	0	62	500 *
85	0	63	380 *
86	0	64	500 *
87	0	65	400 *
88	0	66	300 *
89	0	67	600 *
90	30	68	500 *
91	23	69	380 *
92	9	70	90 *
93	0	71	450 *
94	5	72	450 *
96	36	73	600 *
		127	480 *
		128	20
		129	39
		130	29
		131	0
		132	0
		133	23
		134	5
		135	0
		136	3
		137	18
		138	3
		139	0
		140	0
		141	45
		142	25
		176	1,200 *
		177	210 *
		178	1,500 *

-17-

TABLE I Contd.

Batch 1 - Untreated animals - Control		Batch 2 - Unknown origin - Abattoir	
Sample No.	Result - pg/ml	Sample No.	Result - pg/ml
97	87	74	200 *
98	0	75	1,500 *
99	46	76	900 *
100	5	77	380 *
		179	140 *
		180	120 *
		181	500 *
		182	120 *

Mean value 19.4048

Std Deviation 28.3700

Mean + 3SD = 104 pg/ml


* Denotes values in excess of the
Limit of Decision (104 pg/ml)

- 18 -

Example 2: Cross-reactivity with other Beta-Agonists2. Antibodies

- 5 The Antibodies utilised in the immunoassay and the immunoaffinity columns were raised in both rabbits and sheep respectively, the immunogen being a protein/Clenbuterol conjugate. The general structure of the frequently used beta-agonists is given in Formula I, the meanings of the groups R1 to R4 being given in Table II.

10



20

The cross reactivity of the rabbit antibody used in the immunoassay, determined at a clenbuterol concentration of 1ng/ml is given in Table II.

25

TABLE II

NAME	FUNCTIONAL GROUPS				molwt	% CROSS REACTION
	R1	R2	R3	R		
30 Cimaterol	N≡C	NH ₂	H	H	219.3	1.4
Cimbuterol	N≡C	NH ₂	H	CH ₃	233.3	6.7
Clenbuterol	Cl	NH ₂	Cl	CH ₃	277.2	100
Mabuterol	CF ₃	NH ₂	Cl	CH ₃	310.8	100
35 Mapenterol	CF ₃	NH ₂	Cl	CH ₂ CH ₃	324.8	55
Salbutamol	H	OH	CH ₂ OH	CH ₃	239.0	12.5
Terbutaline	OH	H	OH	CH ₃	225.0	8.3

- 19 -

The cross reactivity of the sheep antibody, used for the immunoaffinity columns, has been determined and found to be approximately:

	Clenbuterol	100%
5	Salbutamol	10.5%
	Terbutaline	6%

The low cross-reactivity for salbutamol and terbutaline is not thought to be a problem as the columns are configured to provide high capacity for all these compounds. The enzyme labelled antibody used for the detection of the "bound" antibody is raised in donkey against rabbit IgG. The IgG was isolated and conjugated to Horseradish Peroxidase.

Example 3: Determination of Hormonal Growth Promoters

15 The preparation of anti-zeranol antibodies was as described in Example 1 but using zeranol in place of clenbuterol and the assay protocol and computation of results is as described previously. Figure 4 shows a standard calibration curve for zeranol from which the amount of zeranol in a bile sample can be determined.

Assay Sensitivity

25 The B_0 value for the assay buffer has been determined on 24 buffer samples analyzed in duplicate, in a single assay. The assay sensitivity is determined as the mean of the B_0 -3 standard deviations (SD), the value obtained is 0.04ng/ml.

Limit of Detection

30 B_0 sample values for 324 control bile samples, obtained from untreated animals of all ages, sexes and sexual maturity etc., were analyzed in 18 clenbuterol assays. The value for the Limit of Detection is 0.055ng/ml and is based on the means B_0 sample value + 2 SD, the mean value $\pm$ SD is $0.029 \pm (2 \times 0.013)$ ng/ml for all samples. A breakdown of the data according to animal type is as follows (ng/ml):

- 20 -

	Steers	Cows	Heifers	Bulls	Total
Mean	0.0296	0.0298	0.0281	0.0223	0.0290
SD	0.0120	0.0131	0.0126	0.0199	0.0127
n	144	76	93	11	324

5

Individual groups of animal do not differ statistically from either of the other groups, or the mean of all of the animals.

The Limit of Determination based on the minimum quantity of
10 clenbuterol detectable with any statistical confidence was determined
by spiking a 11 control bile sample. As the quantity of control bile
was limited, the bile was initially spiked at 0.1ng/ml and the sample
analyzed in replicate. On the basis of the results obtained the
concentration of clenbuterol in the bile was reduced to 0.05ng/ml and
15 the sample re-analyzed in replicate.

0.05ng/ml Spike

Mean = 0.036ng/ml

SD = 0.092

20

Mean Recovery% = 72%

0.1ng/ml Spike

Mean = 0.089 ng/ml

SD = 0.019

= 90%

25

30

35

- 21 -

CLAIMS

1. A method for the rapid detection of drug residues in fresh meat comprising taking a body sample from livestock, reacting the sample in an immunometric assay with a labelled antibody which is capable of reacting with the drug to be detected and determining the amount of labelled antibody bound to the sample, the antibody being labelled with a chromogenic or chemiluminescent label.
2. A method as claimed in claim 1 wherein the body sample is a bile sample.
3. A method as claimed in claim 1 or claim 2 wherein the sample is cleaned prior to immunometric assay by passage through an immunoaffinity column having an immobilised antibody capable of binding the drug to be detected, the column being washed free of impurities and any drug being bound to the column being eluted with a suitable solvent.
4. A method as claimed in any preceding claim wherein the antibody is an anti-clenbuterol antibody.
5. A method as claimed in any of claims 1 to 3 wherein the antibody is an anti-zeranol antibody.
6. A method as claimed in any preceding claim wherein the immunometric assay is a competitive assay in which a solid support is pre-coated with a carrier protein-drug conjugate, the sample and an anti-drug antibody raised in a first species are added to the solid support, allowed to react and the support washed, a labelled anti-first species antibody raised in a second species is added, allowed to react and the support washed, a signal reagent is added and the signal read.
7. A method as claimed in claim 6 wherein the label is horseradish peroxidase.

- 22 -

8. A method as claimed in claim 6 or claim 7 wherein the carrier protein is thyroglobulin.

5 9. A method as claimed in any of claims 6 to 8 wherein the antibody raised in the first species is a rabbit anti-drug antibody and the antibody raised in the second species is a donkey anti-rabbit antibody.

10 10. A method as claimed in any preceding claim which is an enhanced chemiluminescence assay.

11. A method as claimed in any preceding claim wherein the steps are automated, being performed by robots.

15

20

25

30

35

1 / 4






FIG. 1

2/4

CLENBUTEROL STANDARD CURVE
(Using 0.1ml neat bile)

**FIG. 2**

3/4

**FIG. 3****SUBSTITUTE SHEET**

4 / 4

ZERANOL STANDARD CURVE

A/S 1:40k, Label 1:2K




FIG. 4

SUBSTITUTE SHEET

INTERNATIONAL SEARCH REPORT

International Application No

PCT/IE 93/00007

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁶		
According to International Patent Classification (IPC) or to both National Classification and IPC		
Int.Cl. 5 G01N33/94		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
Int.Cl. 5	G01N	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸		
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹		
Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
Y	JOURNAL OF CHROMATOGRAPHY, BIOMEDICAL APPLICATIONS vol. 489, no. 1, 7 April 1989, AMSTERDAM NL pages 157 - 171 W. HAASNOOT ET AL. 'DETERMINATION OF B-19-NORTESTOSTERONE AND ITS METABOLITE a-19-NORTESTOSTERONE IN BIOLOGICAL SAMPLES AT THE SUB PARTS PER BILLION LEVEL BY HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY WITH ON-LINE IMMUNOAFFINITY SAMPLE PRETREATMENT.' see abstract --- -/--	1-11
¹⁰ Special categories of cited documents : ¹⁰ "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
27 MAY 1993	17. 06. 93	
International Searching Authority	Signature of Authorized Officer	
EUROPEAN PATENT OFFICE	CARTAGENA ABELLA P	

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category °	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
Y	JOURNAL OF CHROMATOGRAPHY, BIOMEDICAL APPLICATIONS vol. 489, 1989, AMSTERDAM NL pages 235 - 243 G. DEGAND ET AL. 'ENZYME IMMUNOASSAY SCREENING PROCEDURE FOR THE SYNTHETIC ANABOLIC ESTROGENS AND ANDROGENS DIETHYLSTILBESTROL, NORTESTOSTERONE, METHYLTESTOSTERONE AND TRENBOLONE IN BOVINE URINE.' see the whole document ---	1-11
Y	JOURNAL OF CHROMATOGRAPHY, BIOMEDICAL APPLICATIONS vol. 564, 1991, AMSTERDAM NL pages 551 - 556 H.H.D. MEYER ET AL. 'RESIDUE SCREENING FOR THE B-AGONISTS CLENBUTEROL, SALBUTAMOL AND CIMATEROL IN URINE USING ENZYME IMMUNOASSAY AND HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY.' see the whole document ---	1-11
Y	PATENT ABSTRACTS OF JAPAN vol. 7, no. 42 (P-177)(1187) 10 February 1983 & JP,A,57 192 867 (TEIJIN K. K) 27 November 1982 see abstract ---	1-11
A	ARCHIV FÜR LEBENSMITTELHYGIENE vol. 37, no. 2, March 1986, pages 45 - 48 G. KNUPP ET AL. 'ERFAHRUNGEN MIT EINEM RADIOIMMUNOASSAY ZUM NACHWEIS VON ZERANOL IN HARN, KOT UND GEWEBE VON SCHLACHTTIEREN.' ---	
A	J. VET. PHARMACOL. THERAP. vol. 9, no. 1, 1986, pages 94 - 100 S. N. DIXON ET AL. 'RADIOIMMUNOASSAY OF THE ANABOLIC AGENT ZERANOL.IV. THE DETERMINATION OF ZERANOL CONCENTRATIONS IN THE EDIBLE TISSUES OF CATTLE IMPLANTED WITH ZERANOL.' -----	